⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PSNL News
Personalis, Inc. Common Stock
Form 8-K
sec.gov
PSNL
TEM
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
businesswire.com
TEM
PSNL
Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain
businesswire.com
PSNL
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
businesswire.com
PSNL
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
businesswire.com
PSNL
Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium
businesswire.com
PSNL
Form 8-K
sec.gov
PSNL
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
businesswire.com
PSNL
Personalis to Participate in Upcoming Investor Events
businesswire.com
PSNL
Form 8-K
sec.gov
PSNL